

AMENDMENTS TO THE CLAIMS:

Claim 1. (Currently Amended) A pharmaceutical composition comprising a tablet core, wherein the tablet core comprises an active pharmaceutical ingredient which exists in a first polymorph form susceptible to interconversion into one or more other polymorph forms, and further comprising from about 50% to about 70% by weight silicified microcrystalline cellulose, a stabilizing substance selected from the group consisting of colloidal silicon dioxide, finely divided silicon dioxide, magnesium oxide, calcium oxide, and polyethylene glycol, and optionally one or more pharmaceutically acceptable excipients, wherein the stabilizing substance is present in an amount from about 1 % to about 10 % by weight of the pharmaceutical composition.

Claim 2. (Original) A pharmaceutical composition according to claim 1, wherein said active pharmaceutical ingredient is the potassium salt of losartan.

Claim 3. (Original) A pharmaceutical composition according to claim 2 wherein the potassium salt of losartan is in the amorphous form.

Claim 4. (Original) A pharmaceutical composition according to claim 2 wherein the potassium salt of losartan is in the polymorph form exhibiting its strongest diffractions in a powder X-ray diffractogram at around $2\theta=6.9, 13.8, 20.6, 24.0, 24.8, 28.7$ and 29.2° .

Claim 5. (Previously Presented) A pharmaceutical composition according to claim 1 which is in the form of a coated tablet.

Claim 6. (Previously Presented) A pharmaceutical composition according to claim 5 characterized in that it is coated with a film coating comprising stearic acid or ethylcellulose in an amount of from about 0.1% to about 1.7% by weight of the pharmaceutical composition.

Claim 7. (Currently Amended) A pharmaceutical composition comprising an active pharmaceutical ingredient which exists in a first polymorph form susceptible to interconversion into one or more other polymorph forms, and further comprising from about 50% to about 70% by weight silicified microcrystalline cellulose, a stabilizing substance, and optionally one or more pharmaceutically acceptable excipients, A pharmaceutical composition according to claim 4 wherein said stabilizing substance is finely divided anhydrous silicon dioxide or polyethylene glycol present in amount of 1% to about 10% by weight of the composition.

Claim 8. (Previously Presented) A pharmaceutical composition according to claim 7 which is a finished dosage form comprising from 1 % to about 10% by weight of the composition of finely divided silicon dioxide.

Claim 9. (Previously Presented) A pharmaceutical composition according to claim 8 wherein said finely divided silicon dioxide is Syloid™ silicon dioxide.

Claim 10. (Previously Presented) A pharmaceutical composition according to claim 9 comprising from about 3% to about 10% by weight of the composition of Syloid™ silicon dioxide.

Claim 11-17. (Cancelled)

Claim 18. (Currently Amended) A method for treating hypertension and/or chronic renal failure comprising administering to a patient in need thereof a pharmaceutical composition comprising a tablet core, wherein the tablet core comprises

an active pharmaceutical ingredient which exists in a first polymorph form susceptible to interconversion into one or more other polymorph forms, and further comprising from about 50% to about 70% by weight silicified microcrystalline cellulose, selected from the group consisting of colloidal silicon dioxide, finely divided silicon dioxide, magnesium oxide, calcium oxide, and polyethylene glycol, and optionally one or more pharmaceutically acceptable excipients, wherein the stabilizing substance is present in an amount from about 1 % to about 10 % by weight of the pharmaceutical composition

Claim 19. (Previously Presented) The method according to claim 18 wherein the active pharmaceutical ingredient is a potassium salt of losartan.